Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology with few current treatment options. Recently, we determined an important role of prostaglandin F2α (PGF2α) in pulmonary fibrosis by using a bleomycin-induced pulmonary fibrosis model and found an abunda...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3679025?pdf=render |
id |
doaj-e858837168094d8cb927ce4bd5529e91 |
---|---|
record_format |
Article |
spelling |
doaj-e858837168094d8cb927ce4bd5529e912020-11-25T01:00:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6601710.1371/journal.pone.0066017Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.Kensaku AiharaTomohiro HandaToru OgaKizuku WatanabeKiminobu TanizawaKohei IkezoeYoshio TaguchiHiroe SatoKazuo ChinSonoko NagaiShuh NarumiyaAthol U WellsMichiaki MishimaBACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology with few current treatment options. Recently, we determined an important role of prostaglandin F2α (PGF2α) in pulmonary fibrosis by using a bleomycin-induced pulmonary fibrosis model and found an abundance of PGF2α in bronchoalveolar lavage fluid of IPF patients. We investigated the role of PGF2α in human IPF by assessing plasma concentrations of 15-keto-dihydro PGF2α, a stable metabolite of PGF2α. METHODS: We measured plasma concentrations of 15-keto-dihydro PGF2α in 91 IPF patients and compared these values with those of controls (n = 25). We further investigated the relationships of plasma 15-keto-dihydro PGF2α concentrations with disease severity and mortality. RESULTS: Plasma concentrations of 15-keto-dihydro PGF2α were significantly higher in IPF patients than controls (p<0.001). Plasma concentrations of this metabolite were significantly correlated with forced expiratory volume in 1 second (Rs [correlation coefficient] = -0.34, p = 0.004), forced vital capacity (Rs = -0.33, p = 0.005), diffusing capacity for carbon monoxide (Rs = -0.36, p = 0.003), the composite physiologic index (Rs = 0.40, p = 0.001), 6-minute walk distance (Rs = -0.24, p = 0.04) and end-exercise oxygen saturation (Rs = -0.25, p = 0.04) when patients with emphysema were excluded. Multivariate analysis using stepwise Cox proportional hazards model showed that a higher composite physiologic index (relative risk = 1.049, p = 0.002) and plasma 15-keto-dihydro PGF2α concentrations (relative risk = 1.005, p = 0.002) were independently associated with an increased risk of mortality. CONCLUSIONS: We demonstrated significant associations of plasma concentrations of PGF2α metabolites with disease severity and prognosis, which support a potential pathogenic role for PGF2α in human IPF.http://europepmc.org/articles/PMC3679025?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kensaku Aihara Tomohiro Handa Toru Oga Kizuku Watanabe Kiminobu Tanizawa Kohei Ikezoe Yoshio Taguchi Hiroe Sato Kazuo Chin Sonoko Nagai Shuh Narumiya Athol U Wells Michiaki Mishima |
spellingShingle |
Kensaku Aihara Tomohiro Handa Toru Oga Kizuku Watanabe Kiminobu Tanizawa Kohei Ikezoe Yoshio Taguchi Hiroe Sato Kazuo Chin Sonoko Nagai Shuh Narumiya Athol U Wells Michiaki Mishima Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS ONE |
author_facet |
Kensaku Aihara Tomohiro Handa Toru Oga Kizuku Watanabe Kiminobu Tanizawa Kohei Ikezoe Yoshio Taguchi Hiroe Sato Kazuo Chin Sonoko Nagai Shuh Narumiya Athol U Wells Michiaki Mishima |
author_sort |
Kensaku Aihara |
title |
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
title_short |
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
title_full |
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
title_fullStr |
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
title_full_unstemmed |
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
title_sort |
clinical relevance of plasma prostaglandin f2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology with few current treatment options. Recently, we determined an important role of prostaglandin F2α (PGF2α) in pulmonary fibrosis by using a bleomycin-induced pulmonary fibrosis model and found an abundance of PGF2α in bronchoalveolar lavage fluid of IPF patients. We investigated the role of PGF2α in human IPF by assessing plasma concentrations of 15-keto-dihydro PGF2α, a stable metabolite of PGF2α. METHODS: We measured plasma concentrations of 15-keto-dihydro PGF2α in 91 IPF patients and compared these values with those of controls (n = 25). We further investigated the relationships of plasma 15-keto-dihydro PGF2α concentrations with disease severity and mortality. RESULTS: Plasma concentrations of 15-keto-dihydro PGF2α were significantly higher in IPF patients than controls (p<0.001). Plasma concentrations of this metabolite were significantly correlated with forced expiratory volume in 1 second (Rs [correlation coefficient] = -0.34, p = 0.004), forced vital capacity (Rs = -0.33, p = 0.005), diffusing capacity for carbon monoxide (Rs = -0.36, p = 0.003), the composite physiologic index (Rs = 0.40, p = 0.001), 6-minute walk distance (Rs = -0.24, p = 0.04) and end-exercise oxygen saturation (Rs = -0.25, p = 0.04) when patients with emphysema were excluded. Multivariate analysis using stepwise Cox proportional hazards model showed that a higher composite physiologic index (relative risk = 1.049, p = 0.002) and plasma 15-keto-dihydro PGF2α concentrations (relative risk = 1.005, p = 0.002) were independently associated with an increased risk of mortality. CONCLUSIONS: We demonstrated significant associations of plasma concentrations of PGF2α metabolites with disease severity and prognosis, which support a potential pathogenic role for PGF2α in human IPF. |
url |
http://europepmc.org/articles/PMC3679025?pdf=render |
work_keys_str_mv |
AT kensakuaihara clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT tomohirohanda clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT toruoga clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT kizukuwatanabe clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT kiminobutanizawa clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT koheiikezoe clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT yoshiotaguchi clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT hiroesato clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT kazuochin clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT sonokonagai clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT shuhnarumiya clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT atholuwells clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis AT michiakimishima clinicalrelevanceofplasmaprostaglandinf2ametaboliteconcentrationsinpatientswithidiopathicpulmonaryfibrosis |
_version_ |
1725214894949662720 |